- Home
- ZNTL vs PKE Comparison
ZNTL vs PKE Comparison
Compare ZNTL & PKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- PKE
- Stock Information
- Founded
- ZNTL 2014
- PKE 1954
- Country
- ZNTL United States
- PKE United States
- Employees
- ZNTL N/A
- PKE N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- PKE Military/Government/Technical
- Sector
- ZNTL Health Care
- PKE Industrials
- Exchange
- ZNTL Nasdaq
- PKE Nasdaq
- Market Cap
- ZNTL 238.2M
- PKE 277.5M
- IPO Year
- ZNTL 2020
- PKE N/A
- Fundamental
- Price
- ZNTL $3.12
- PKE $14.41
- Analyst Decision
- ZNTL Buy
- PKE
- Analyst Count
- ZNTL 7
- PKE 0
- Target Price
- ZNTL $10.86
- PKE N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- PKE 87.5K
- Earning Date
- ZNTL 11-04-2024
- PKE 10-15-2024
- Dividend Yield
- ZNTL N/A
- PKE 3.48%
- EPS Growth
- ZNTL N/A
- PKE N/A
- EPS
- ZNTL N/A
- PKE 0.34
- Revenue
- ZNTL $40,560,000.00
- PKE $58,651,000.00
- Revenue This Year
- ZNTL N/A
- PKE N/A
- Revenue Next Year
- ZNTL N/A
- PKE N/A
- P/E Ratio
- ZNTL N/A
- PKE $42.64
- Revenue Growth
- ZNTL N/A
- PKE 5.81
- 52 Week Low
- ZNTL $2.83
- PKE $11.96
- 52 Week High
- ZNTL $18.24
- PKE $16.96
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- PKE 62.75
- Support Level
- ZNTL $2.92
- PKE $13.20
- Resistance Level
- ZNTL $3.23
- PKE $15.20
- Average True Range (ATR)
- ZNTL 0.17
- PKE 0.38
- MACD
- ZNTL 0.00
- PKE 0.15
- Stochastic Oscillator
- ZNTL 38.33
- PKE 65.60
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.